Peter Salzmann, M.D., MBA, served as Chief Executive Officer of Immunovant Inc., a clinical-stage biotechnology company dedicated to developing novel therapies for autoimmune diseases. With more than two decades of experience in the pharmaceutical and biotech sectors, Salzmann previously held senior leadership roles at Roivant Sciences and other organizations, where he focused on clinical development, medical affairs, and strategic partnerships that advanced multiple drug candidates through regulatory and commercialization stages. His key achievements include guiding Immunovant’s lead asset, batoclimab, through pivotal clinical trials targeting conditions such as myasthenia gravis and thyroid eye disease, while expanding the company’s pipeline and securing significant funding rounds to support growth. Salzmann’s leadership emphasized rigorous scientific execution and patient-focused innovation, helping position Immunovant as a notable player in the immunology space. As former CEO, he played a central role in shaping the company’s strategic direction, fostering collaborations with academic and industry partners, and driving operational excellence prior to transitioning from the position. His background in both clinical medicine and business strategy has been instrumental in bridging scientific discovery with commercial viability.